| Popis: |
Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common lymphoid neoplasm in adults. It accounts for 30% of Non-Hodgkin's lymphomas (NHLs) diagnosed annually [1].The present study aims to evaluate the outcome of the patients who received CHOP(Cyclophosphamide, Adriamycin, Vincristine, Prednisolone) and R(Rituximab)-CHOP treatment and also correlates the different patient characteristics. This was a retrospective analysis carried out on 65 pat Materials & Methods: ients, diagnosed with DLBCL treated from December 2013 to July 2019. A total of 65 cases were studied and their different Results: clinical characteristics are presented in (Table 1). The median age of the study population was 44 years (19–75 years). The male-to-female ratio was 1:0.5. 3year OS (overall survival) was 32% and 43% in CHOP and R-CHOP group and statistically, a signicant difference was seen in both the groups p |
